视网膜静脉阻塞换用阿柏西普8mg的真实世界疗效
RISE-RVO研究纳入156只视网膜静脉阻塞眼,从其他抗VEGF治疗换用超适应症阿柏西普8mg并采用观察-计划方案。12个月时平均注射间隔延长1.6周,短间隔(≤6周)比例从37.8%降至17.9%,长间隔(≥9周)比例从37.8%升至60.3%,黄斑中心厚度下降,视力保持不变。
要点
- 换用阿柏西普8mg后12个月平均间隔延长+1.6周,短间隔比例显著下降。
- CRVO亚组间隔延长+2.0周,BRVO亚组+1.3周;换药时黄斑干燥者延长更明显。
- 黄斑中心厚度从262.8±79.4µm降至244.6±59.5µm,视力维持68.2个ETDRS字母。
核心结论
- 换用阿柏西普8mg可显著减少短间隔治疗眼比例,且不损害视力结局。
研究设计与样本
- 基于医疗记录回顾的观察性研究,纳入156只RVO眼(BRVO 91只,CRVO 65只),从其他抗VEGF治疗换用超适应症阿柏西普8mg,采用观察-计划方案,随访12个月。
主要发现
- 总体队列12个月平均间隔延长+1.6周(p<0.0001)。
- ≤6周间隔比例从37.8%降至17.9%(p<0.0001),≥9周间隔比例从37.8%升至60.3%(p<0.0001)。
- CRVO亚组12个月间隔平均延长+2.0周(p<0.0001),换药时黄斑干燥者延长+3.0周(p<0.0001)。
- BRVO亚组间隔平均延长+1.3周(p<0.0001),换药时黄斑干燥者延长+2.3周(p<0.0001)。
- 黄斑中心厚度从262.8±79.4µm降至244.6±59.5µm(p=0.0012),最佳记录视力维持68.2个ETDRS字母不变。
关键数值与推荐
- 纳入标准:既往抗VEGF注射≥10次且持续治疗的眼;12个月随访期间中断治疗者排除。
- 主要结局指标:注射间隔变化、≤6周和≥9周间隔比例、黄斑中心厚度、最佳记录视力。
临床怎么用
- 对既往频繁注射的RVO眼,换用阿柏西普8mg可能延长治疗间隔并减少注射负担,尤其换药时黄斑干燥者。
- 换药后需按观察-计划方案密切随访,视力可维持稳定。
局限性
- 回顾性研究设计,样本来自单中心医疗记录,存在选择偏倚。
- 阿柏西普8mg为超适应症使用,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Evaluation of durability outcomes after switching to aflibercept 8 mg for macular oedema in retinal vein occlusion (RVO). METHODS: We evaluated eyes with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), switching from other anti-vascular endothelial growth factor treatments to off-label aflibercept 8 mg under an observe-and-plan regimen. Eyes receiving ongoing treatment with ≥10 prior injections were eligible. Treatment discontinuation during the 12-month follow-up period resulted in exclusion. All data were obtained through the review of medical records. RESULTS: The overall cohort of eyes with RVO (n=156) achieved a mean interval gain of +1.6 weeks at 12 months (p<0.0001). The proportion of eyes treated at ≤6-week intervals decreased from 37.8% at switch to 17.9% at 12-month follow-up (p<0.0001) while the proportion on intervals ≥9 weeks increased from 37.8% at switch to 60.3% (p<0.0001). The CRVO subgroup (n=65) achieved a mean increase in interval length at 12 months of +2.0 weeks (p<0.0001) and +3.0 weeks in the case of a dry macula at switch (p<0.0001). The BRVO subgroup (n=91) achieved an overall increase in interval length of +1.3 weeks (p<0.0001) and +2.3 weeks for eyes with a dry macula at switch (p<0.0001). The central retinal thickness decreased from 262.8±79.4 µm to 244.6±59.5 µm (p=0.0012) while best recorded visual acuity remained unchanged at 68.2 Early Treatment Diabetic Retinopathy Study letters at 12 months. CONCLUSION: Switching to aflibercept 8 mg substantially reduced the proportion of eyes on short intervals without compromising visual outcomes.
引用
- Nguyen CT, Lassen RKB, Mæng MO, et al. Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes. Br J Ophthalmol. 2026. PMID: 42309665. doi:10.1136/bjo-2025-329273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。